PL2424870T3 - Środki terapeutyczne 713 - Google Patents

Środki terapeutyczne 713

Info

Publication number
PL2424870T3
PL2424870T3 PL10718670T PL10718670T PL2424870T3 PL 2424870 T3 PL2424870 T3 PL 2424870T3 PL 10718670 T PL10718670 T PL 10718670T PL 10718670 T PL10718670 T PL 10718670T PL 2424870 T3 PL2424870 T3 PL 2424870T3
Authority
PL
Poland
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Application number
PL10718670T
Other languages
English (en)
Inventor
Lars Anders Mikael Johansson
Robert Andrew Judkins
Lanna Li
Bjorn Christian Ingvar Lofberg
Joachim Persson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL2424870T3 publication Critical patent/PL2424870T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
PL10718670T 2009-05-01 2010-04-29 Środki terapeutyczne 713 PL2424870T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17463009P 2009-05-01 2009-05-01
PCT/GB2010/050698 WO2010125390A1 (en) 2009-05-01 2010-04-29 Therapeutic agents 713
EP10718670.2A EP2424870B1 (en) 2009-05-01 2010-04-29 Therapeutic agents 713

Publications (1)

Publication Number Publication Date
PL2424870T3 true PL2424870T3 (pl) 2016-05-31

Family

ID=42290768

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10718670T PL2424870T3 (pl) 2009-05-01 2010-04-29 Środki terapeutyczne 713

Country Status (23)

Country Link
US (1) US8110566B2 (pl)
EP (1) EP2424870B1 (pl)
JP (1) JP5763052B2 (pl)
KR (1) KR20120023044A (pl)
CN (2) CN103936751A (pl)
AR (1) AR076516A1 (pl)
AU (1) AU2010243341B2 (pl)
BR (1) BRPI1014387A2 (pl)
CA (1) CA2759230A1 (pl)
DK (1) DK2424870T3 (pl)
ES (1) ES2562831T3 (pl)
HR (1) HRP20160128T1 (pl)
HU (1) HUE026856T2 (pl)
MX (1) MX2011011618A (pl)
PL (1) PL2424870T3 (pl)
PT (1) PT2424870E (pl)
RU (1) RU2526055C2 (pl)
SA (1) SA110310332B1 (pl)
SI (1) SI2424870T1 (pl)
SM (1) SMT201600041B (pl)
TW (1) TW201100433A (pl)
UY (1) UY32593A (pl)
WO (1) WO2010125390A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049864A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
AU2011275547B2 (en) 2010-07-06 2015-10-29 Astrazeneca Ab Therapeutic agents 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
KR102866499B1 (ko) 2019-03-15 2025-10-02 더 제너럴 하스피탈 코포레이션 Tead 전사인자의 신규한 소분자 저해제
EP4076527A4 (en) * 2020-01-10 2024-05-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1625554A (zh) * 2002-02-01 2005-06-08 诺沃挪第克公司 氨基烷基-取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
JP4595542B2 (ja) * 2002-07-30 2010-12-08 萬有製薬株式会社 ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US7241787B2 (en) * 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
CA2575081C (en) * 2004-07-26 2013-05-07 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
JP5057982B2 (ja) 2004-10-18 2012-10-24 イーライ リリー アンド カンパニー ヒスタミンh3受容体阻害剤、製造及び治療的使用
DE602005009021D1 (de) 2004-12-17 2008-09-25 Lilly Co Eli Neue mch-rezeptorantagonisten
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
CA2610671A1 (en) * 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
CN101400677A (zh) * 2006-01-06 2009-04-01 阿斯利康(瑞典)有限公司 化合物
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Mchr1アンタゴニストとしてのチエノピリミジン−4−オン誘導体およびチエノピリダジン−7−オン誘導体
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
EA015559B1 (ru) 2006-12-14 2011-08-30 Эли Лилли Энд Компани ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
EP2148931A2 (en) 2007-04-17 2010-02-03 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
ATE519738T1 (de) 2007-08-22 2011-08-15 Hoffmann La Roche Pyrrolidinarylether als nk3-rezeptorantagonisten
ES2372332T3 (es) * 2007-10-17 2012-01-18 Sanofi N-fenil-bipirrolidina carboxamidas sustituidas y su uso terapéutico.
JPWO2009154132A1 (ja) * 2008-06-19 2011-12-01 Msd株式会社 スピロジアミン−ジアリールケトオキシム誘導体

Also Published As

Publication number Publication date
WO2010125390A1 (en) 2010-11-04
HUE026856T2 (en) 2016-07-28
US20100280000A1 (en) 2010-11-04
ES2562831T3 (es) 2016-03-08
KR20120023044A (ko) 2012-03-12
UY32593A (es) 2010-11-30
MX2011011618A (es) 2011-11-18
AU2010243341B2 (en) 2014-02-13
JP5763052B2 (ja) 2015-08-12
CN102459279B (zh) 2014-06-25
EP2424870B1 (en) 2015-12-16
CN102459279A (zh) 2012-05-16
CA2759230A1 (en) 2010-11-04
BRPI1014387A2 (pt) 2017-06-06
TW201100433A (en) 2011-01-01
SA110310332B1 (ar) 2013-12-10
SI2424870T1 (sl) 2016-03-31
CN103936751A (zh) 2014-07-23
AR076516A1 (es) 2011-06-15
EP2424870A1 (en) 2012-03-07
PT2424870E (pt) 2016-03-17
AU2010243341A1 (en) 2011-11-03
RU2526055C2 (ru) 2014-08-20
DK2424870T3 (en) 2016-02-15
SMT201600041B (it) 2016-02-25
JP2012525365A (ja) 2012-10-22
HRP20160128T1 (hr) 2016-02-26
US8110566B2 (en) 2012-02-07

Similar Documents

Publication Publication Date Title
GB0811304D0 (en) Therapeutic agents
GB0908957D0 (en) Therapeutic agents
GB0811643D0 (en) New therapeutic agents
GB0819593D0 (en) Therapeutic agents
IL201235A0 (en) Therapeutic agents
GB0921075D0 (en) Novel combination of the therapeutic agents
GB0801081D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0723747D0 (en) Therapeutic agents
GB0801080D0 (en) Therapeutic agents
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0724340D0 (en) Novel Therapeutic Agents
PT2424870E (pt) Agentes terapêuticos 713
EP2454276A4 (en) THERAPEUTIC AGENTS
GB0723748D0 (en) Therapeutic agents
GB0910493D0 (en) Therapeutic agents
GB0811715D0 (en) Therapeutic agents
GB0911965D0 (en) Therapeutic agents
GB0919819D0 (en) Therapeutic agents
GB0914533D0 (en) Therapeutic agents
GB0903949D0 (en) Therapeutic agents
GB0907971D0 (en) Therapeutic agents
GB0915586D0 (en) Therapeutic agents
GB0919820D0 (en) Therapeutic agents